VERA

Vera Therapeutics, Inc. Class A Common Stock

$33.94 -4.45%

Recent alerts on VERA

All signals →

News Vera (VERA) Q2 Net Loss Widens 127%

News Analysts Can't Get Enough of These Little-Known Biopharma Stocks

News Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market

Insider trade Sale by Marshall Fordyce (PRESIDENT AND CEO)

News Vera Therapeutics GAAP EPS of -$1.69

SEC filing VERA Reports $596.8M Cash, $1.69 EPS Loss, FDA Priority Review for Atacicept in IgAN, July 7 2026 PDUFA, Mid‑2026 Launch, $121M Q1 Net Loss

Insider trade Sale by Marshall Fordyce (PRESIDENT AND CEO)

News This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Insider trade Sale by Laurence Matthew Skelton (Chief Commercial Officer)

Insider trade Sale by William D. Turner (Chief Regulatory Officer)

Insider trade Sale by David Lee Johnson (Chief Operating Officer)

Insider trade Sale by Marshall Fordyce (PRESIDENT AND CEO)

Insider trade Sale by Sean Grant (CHIEF FINANCIAL OFFICER)

Insider trade Sale by Joseph R Young (SVP, FINANCE, CHIEF ACCT OFFCR)

Insider trade Sale by Robert Brenner (Chief Medical Officer)

News Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept

News Verana Health Merges with COTA to Dramatically Expand Scale, Velocity, and Depth of Real-World Data Offerings Across Oncology and Other Specialties

News Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

News Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Get push alerts for VERA

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS